# A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis

> **NCT00230529** · PHASE2 · COMPLETED · sponsor: **Centocor, Inc.** · enrollment: 249 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** infliximab

## Key facts

- **NCT ID:** NCT00230529
- **Lead sponsor:** Centocor, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** 2003-01
- **Target enrollment:** 249 (ACTUAL)
- **Last updated:** 2011-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00230529

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00230529, "A Safety and Efficacy Study of Infliximab (Remicade) in Patients With Plaque Type Psoriasis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT00230529. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*